FY2025 EPS Forecast for Gilead Sciences Raised by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities research analysts at Cantor Fitzgerald increased their FY2025 earnings per share estimates for shares of Gilead Sciences in a report released on Wednesday, February 19th. Cantor Fitzgerald analyst O. Brayer now anticipates that the biopharmaceutical company will earn $7.98 per share for the year, up from their prior estimate of $7.24. Cantor Fitzgerald has a “Neutral” rating and a $80.00 price target on the stock. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.94 per share.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%.

Several other brokerages also recently commented on GILD. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. Bank of America reissued a “buy” rating and set a $109.00 price objective on shares of Gilead Sciences in a report on Tuesday, December 10th. Royal Bank of Canada raised their price target on Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. UBS Group raised their price target on Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Finally, Piper Sandler raised their price target on Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $102.08.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $110.03 on Friday. The company has a market cap of $137.13 billion, a PE ratio of 297.38, a price-to-earnings-growth ratio of 0.90 and a beta of 0.18. Gilead Sciences has a 52 week low of $62.07 and a 52 week high of $110.11. The business has a 50 day moving average price of $95.05 and a 200-day moving average price of $88.38. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Institutional Investors Weigh In On Gilead Sciences

A number of hedge funds have recently added to or reduced their stakes in GILD. AMF Tjanstepension AB raised its stake in Gilead Sciences by 14.7% during the 3rd quarter. AMF Tjanstepension AB now owns 400,819 shares of the biopharmaceutical company’s stock valued at $33,645,000 after buying an additional 51,390 shares during the last quarter. Swedbank AB raised its stake in Gilead Sciences by 10.2% during the 3rd quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company’s stock valued at $171,672,000 after buying an additional 189,622 shares during the last quarter. nVerses Capital LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $25,000. Eastern Bank bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $90,000. Finally, BLB&B Advisors LLC bought a new stake in shares of Gilead Sciences during the 3rd quarter valued at $221,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Gilead Sciences

In related news, insider Merdad Parsey sold 164,211 shares of the business’s stock in a transaction that occurred on Wednesday, November 27th. The shares were sold at an average price of $91.92, for a total value of $15,094,275.12. Following the completion of the transaction, the insider now directly owns 80,801 shares in the company, valued at $7,427,227.92. The trade was a 67.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $92.76, for a total transaction of $23,064,310.20. Following the completion of the transaction, the chief financial officer now owns 138,919 shares of the company’s stock, valued at approximately $12,886,126.44. The trade was a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 713,000 shares of company stock valued at $67,945,181 in the last ninety days. 0.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.87%. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences’s payout ratio is presently 832.43%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.